Recent Company News

• 10:09 PM ET Feb 17, 2026
  

  StreetAccount Scorecard - Australian ASX200 short interest as at 12-Feb

• 06:10 PM ET Feb 11, 2026
  

  Mesoblast presents study results showing that Ryoncil achieved high survival outcomes in SR-aGvHD (A$2.55, -0.02)

• 06:10 PM ET Jan 28, 2026
  

  Mesoblast reports Q2 net cash from / (used in) operating activities ($15.6M) - Appendix 4C (A$2.68, -0.02)

• 06:29 PM ET Jan 26, 2026
  

  Mesoblast issues post-launch Ryoncil update; 84% survival of children with SR-aGvHD after completing 28-days of treatment (A$2.63, -0.05)

• 07:34 PM ET Jan 08, 2026
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 06:12 PM ET Jan 18, 2026
  

  Mesoblast receives FDA feedback on potential BLA filing for rexlemestrocel-L in patients with chronic discogenic low back pain (A$2.64, 0.00)

• 10:02 AM ET Jan 09, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (223 total)

• 10:58 PM ET Jan 08, 2026
  

  StreetAccount Summary: Australia and New Zealand Stocks reaching new 52-week highs/lows (31 total)